COMP <GO>
GILD vs ABBV // GROSS PROFIT MARGIN
Gilead Sciences Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: GILD 10
— ABBV 5
▲ GROSS PROFIT MARGIN LEADER: GILD
LAST: $170.68 (+3.06%) • MKT CAP: $205.35B
gross-margins
78.80%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GILD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GILD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 78.80% | 70.20% | +8.60 | GILD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.00% | 29.00% | -8.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 33.3x | -12.30 | GILD | /valuation <GO> |
| Free Cash Flow Yield | 4.60% | 3.47% | +1.13 | GILD | /fcf-yield <GO> |
| Operating Margin | 34.00% | 24.60% | +9.40 | GILD | /operating-margins <GO> |
| Net Profit Margin | 28.90% | 6.90% | +22.00 | GILD | /net-margins <GO> |
| Revenue Growth (YoY) | 2.40% | 8.60% | -6.20 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.95% | 2.27% | -0.32 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.87 | 5.33 | +0.54 | GILD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | GILD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.40% | -0.90 | GILD | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 74.3 | 72.8 | +1.50 | GILD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.15 | -0.27 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.4x | 113.1x | -90.70 | GILD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $205.35B | $513.86B | -$308.51B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GILD REV | ABBV REV | GILD GROSS % | ABBV GROSS % | GILD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $29.44B | $61.16B | 78.8% | 70.2% | $9.46B | $17.82B |
| FY 2024 | $28.75B | $56.33B | 78.3% | 70.0% | $10.30B | $17.83B |
| FY 2023 | $27.12B | $54.32B | 44.0% | 44.0% | $6.79B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GILD // BETA 0.88
ABBV // BETA 1.15